# Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

> **NCT03484923** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 196 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** PDR001
- **DRUG:** LAG525
- **DRUG:** INC280
- **DRUG:** ACZ885
- **DRUG:** LEE011

## Key facts

- **NCT ID:** NCT03484923
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-10
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 196 (ACTUAL)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03484923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03484923, "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03484923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*